

CURRICULUM VITAE

BRUCE LAURENCE LAMBERT

Last Updated: September 2009

Personal Data

Home:	BLL Consulting, Inc. or Pharm I. R., Inc. 1427 Lathrop Avenue River Forest, IL 60305-1119	Office:	Dept. of Pharmacy Administration University of Illinois at Chicago (MC 871) 833 South Wood Street, Rm. 241 Chicago, IL 60612-7231
Phone:	708-305-3383	Phone:	312-996-2411
Fax:	708-209-1336	Fax:	312-996-0868
E-mail:	brucelamb@gmail.com	Cell:	708-305-3383
		E-mail:	lambertb@uic.edu

Education

Ph. D. Speech Communication, University of Illinois at Urbana-Champaign, 1992
Dissertation: "A Connectionist Model of Message Design"
Major Advisor: Barbara J. O'Keefe, Ph.D.

A. M. Speech Communication, University of Illinois at Urbana-Champaign, 1988

A. B. Speech Communication, University of Illinois at Urbana-Champaign, 1987
Phi Beta Kappa, Magna cum Laude, with High Distinction in Speech Communication

Academic Employment

University of Illinois at Chicago

Director of Research, UIC Institute for Patient Safety Excellence, 2008–present

Director of Research, Department of Pharmacy Administration, 2007–present

Professor, Department of Pharmacy Administration, 2006–present

Clinical Professor, Department of Pharmacy Practice, 2007–present

Adjunct Professor, Department of Communication, 2006–present

Adjunct Associate Professor, Department of Communication, 2004–2006

Associate Professor, Department of Pharmacy Administration, 1998–2006

Clinical Associate Professor, Department of Pharmacy Practice, 1998–2006

Acting Head, Department of Pharmacy Administration, 1998–2001

Clinical Assistant Professor, Department of Pharmacy Practice, 1994–1998

Adjunct Assistant Professor, Department of Communication, 1993–1996

Assistant Professor, Department of Pharmacy Administration, 1992–1998

Lecturer, Department of Pharmacy Administration, 1991–1992

Non-Academic Employment

President, Pharm I. R., Inc., 2004–present

President, BLL Consulting, Inc., 2001–present

Honors

American Academy of Family Physicians' Family Medicine Research Presentation Award (2nd Place), 2008

Inaugural Member, UIC Center for Clinical and Translational Science, Translational Research Academy, 2008–present

Fellow, Institute of Medicine of Chicago, 2007–present

Center Director's Special Citation Award (with Dan Boring, PhD), Center for Drug Evaluation Research,

U.S. FDA, November, 1998.
Institute for Safe Medication Practices “Cheers Award” for outstanding leadership in preventing adverse drug events, December, 1998.
Literature Award, Foundation of Illinois Pharmacists, September, 1998.
Best Published Paper of 1997, Economic, Social and Administrative Sciences Section, American Pharmaceutical Association (APhA), March, 1998.
New Investigator Award, American Association of Colleges of Pharmacy, 1992.
Graduate College Fellow, University of Illinois at Urbana-Champaign, 1987-1991.
Member, *Phi Beta Kappa*, 1987-present.

Professional Service

Research Program, National Patient Safety Foundation, 2002–present, Co-Chair, 2007–2008, Chair, 2008–present
Member, Adverse Event Advisory Committee, Illinois Department of Public Health, 2008–present
Member, Board of Trustees, Med-E.R.R.S., Inc. 2006–present
Member, Medication Safety Expert Panel, The Joint Commission, 2006-2008
Steering Committee, Chicago Patient Safety Forum, 2002–2006 (Founding member)
Ad Hoc grant reviewer—Clinical Informatics for Patient Safety, U. S. Agency for Healthcare Research and Quality (AHRQ), 2001; National Patient Safety Foundation, 2002–present, Patient Safety Challenge Grants (AHRQ), 2003; Health Informatics Planning Grants (AHRQ), 2004.
Editorial board member, *Health Communication*
Faculty Delegate, American Association of Colleges of Pharmacy, 1995–1996
Member, Consumer Interest and Health Education Advisory Panel, U. S. Pharmacopeia, 1995–2000
Consultant (Special Government Employee), Labeling and Nomenclature Committee, Center for Drug Evaluation Research, U. S. Food and Drug Administration, 1997–2000
Ad Hoc reviewer for *JAMA*, *Medical Care*, *Social Science & Medicine*, *Schizophrenia Research*, *Patient Education and Counseling*, *Human Communication Research*, *Archives of Internal Medicine*, *Drug Safety*, *Human Factors*, *Journal of Postgraduate Medical Education*, *Social Sciences and Humanities Research Council of Canada*, *Journal of General Internal Medicine*, *Perceptual and Motor Skills*, *American Pharmacists Association*, *Applied Ergonomics*, *Pediatrics*

Journal Articles

1. Schiff, G. D., Hasan, O., Kim, S., Abrams, R., Cosby, K., Lambert, B. L., Elstein, A. S., Hasler, S., Kabongo, M. L., Krosnjar, N., Odwazny, R., Wisniewski, M. F., McNutt, R. A. (in press). Diagnostic error in medicine: Analysis of 583 physician-reported errors. *Archives of Internal Medicine*.
2. Chermak, T. E. & Lambert, B. L. (2009). Descriptive analysis of primary package labels from commercially available prescription solid oral dosage form drugs. *Journal of the American Pharmacists Association*, 49(3), 399-406.
3. Hung, S.-H., Pickard, S., Witt, W.P., & Lambert, B.L. (2007). Pain and depression in caregivers affects their perception of pain in stroke patients. *Journal of Clinical Epidemiology*, 60(9), 963-970.
4. Lambert, B. L., Cunningham, F. E, Miller, D. R., Dalack, G. W., & Hur, K. (2006). Diabetes risk associated with use of olanzapine, quetiapine and risperidone in VA patients with schizophrenia. *American Journal of Epidemiology*, 164, 672-681.
5. Lin, S.-J., Lambert, B., Tan, H., & Toh, S. (2006). Frequency estimates from prescription drug datasets. *Pharmacoepidemiology and Drug Safety*, 15, 512-520.
6. Viswanathan, H. & Lambert, B. L. (2005). An inquiry into medication meanings, illness, medication use, and the transformative potential of chronic illness among African Americans

- with hypertension. *Research in Social and Administrative Pharmacy*, 1, 21-39.
7. Lambert, B. L., Chou, C.-H., Chang, K.-Y., Tafesse, E., & Carson, W. (2005). Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: A matched case-control study of California Medicaid claims. *Journal of Pharmacoepidemiology and Drug Safety*, 14, 417-425.
 8. Lambert, B. L., Lin, S.-J., & Tan, H. K. (2005). Designing safe drug names. *Drug Safety*, 28, 495-512.
 9. Lambert, B. L., Chang, K.-Y., Tafesse, E., & Carson, W. (2005). Association between antipsychotic treatment and hyperlipidemia among California Medicaid patients with schizophrenia. *Journal of Clinical Psychopharmacology*, 25, 12-18.
 10. Bonito, J. A., & Lambert, B. L. (2005). Information similarity is a moderator on the effect of gender on participation in small groups: A multilevel analysis. *Small Group Research*, 36, 139-165.
 11. Lambert, B. L., Yu, C., Thirumulai, M. (2004). A system for multiattribute drug product comparison. *Journal of Medical Systems*, 28(1), 29-54.
 12. Lambert, B. L., Chang, K.-Y., Gupta, P. (2003). Effects of frequency and similarity neighborhoods on pharmacists' visual perception of drug names. *Social Science & Medicine*, 57, 1939-1955.
 13. Lambert, B. L., Chang, K.-Y., & Lin, S.-J. (2003). Immediate free recall of drug names: Effects of similarity and availability. *American Journal of Health-System Pharmacy*, 60, 156-168
 14. Lambert, B. L., Donderi, D., & Senders, J. (2002). Similarity of drug names: Objective and subjective measures. *Psychology & Marketing*, 19 (7-8), 641-661.
 15. Brewer, W. F., & Lambert, B. L. (2001). The theory-ladenness of observation and the theory-ladenness of the rest of the scientific process. *Philosophy of Science*, 68 (3), S176-S186.
 16. Gandhi, S. K., Salmon, J. W., Zhao, S. Z., Lambert, B. L., Gore, P. R., Conrad, K. (2001). Psychometric evaluation of the 12-item short-form health survey (SF-12) in osteoarthritis and rheumatoid arthritis clinical trials. *Clinical Therapeutics*, 23 (7), 1080-1098.
 17. Lambert, B. L., Chang, K.-Y., & Lin, S.-J. (2001). Effect of orthographic and phonological similarity on false recognition of drug names. *Social Science & Medicine*, 52, 1843-1857.
 18. Lambert, B. L., Chang, K.-Y., Lin, S.-J. (2001). Descriptive analysis of the drug name lexicon. *Drug Information Journal*, 35, 163-172.
 19. Lambert, B. L., Butin, D. N., Moran, D., Zhao, S. Z., Carr, B. C., Chen, C., Kizis, F. J. (2000). Arthritis care: Comparison of physicians' and patients' views. *Seminars in Arthritis and Rheumatism*, 30 (2), 100-110.
 20. Lambert, B. L., Lin, S.-J., Chang, K.-Y., & Gandhi, S. K. (1999). Similarity as a risk factor in drug name confusion errors: The look-alike (orthographic) and sound-alike (phonetic) model. *Medical Care*, 37(12), 1214-1225.
 21. Lambert, B. L. (1998). Pharmacist-physician communication. *International Pharmacy*, 12, 53-56.
 22. Lambert, B. L., Salmon, J. W., Stubbings, J., Gilomen-Study, G., Valuck, R., & Kezlarian, K. (1997). Factors associated with antibiotic prescribing in a managed care setting: An exploratory investigation. *Social Science & Medicine*, 45, 1767-1779.
 23. Lewis, R. K., Lasack, N. L., Lambert, B. L., & Connor, S. (1997). Patient counseling: A focus on maintenance therapy. *American Journal of Health-System Pharmacy*, 54, 2084-2098.
 24. Lambert, B. L. (1997). Predicting look-alike and sound-alike medication errors. *American Journal of Health-System Pharmacy*, 54, 1161-1171.
 25. Lambert, B. L., Street, R. Jr., Cegala, D., Smith, D., Kurtz, S., & Schofield, T. (1997). Provider-patient communication, patient-centered care, and the mangle of practice. *Health*

- Communication*, 9, 27-43.
26. Lambert, B. L. (1996). Face and politeness in pharmacist-physician interaction. *Social Science & Medicine*, 43(8), 1189-1198.
 27. Luo, A. Y., Salmon, J. W., Lambert, B. L. (1996). U.S. pharmaceutical firm prospects within the People's Republic of China. *Journal of Managed Care Pharmacy*, 2, 76-81.
 28. Lambert, B. L. (1995). Directness and deference in pharmacy students' messages to physicians. *Social Science & Medicine*, 40(4), 545-555.
 29. Lambert, B. L., & Gillespie, J. L. (1994). Patient perceptions of pharmacy students' hypertension compliance gaining messages: Effects of message design logic and content themes. *Health Communication*, 6(4), 311-325.
 30. Hammond, S. L., & Lambert, B. L. (1994). Communicating about medications: Directions for research. *Health Communication*, 6(4), 247-251.
 31. Hammond, S. L., & Lambert, B. L. (Eds.). (1994). Communicating with patients about their medications [Special issue]. *Health Communication*, 6(4).

Journal Articles (in progress)

1. Galanter, W., Liu, X., Lambert, B. L. (under revision). An analysis of computer alerts suggesting oral medication use during computerized order entry of intravenous medications. *American Journal of Health-System Pharmacy*.
2. Lambert, B. L., Dickey, L. W., Fisher, W. M., Gibbons, R. D., Lin, S.-J., Luce, P. A., McClennan, C. T., Senders, J. W., Yu, C. T. (submitted). Listen carefully: The risk of error in spoken medication orders. *Social Science & Medicine*.
3. Galanter, W. T., Thambi, M., Rosencranz, H., Shah, B., Falck, S., Lin, F.-J., Nutescu, E., Lambert, B. L. (submitted). Clinical decision support to improve venous thromboembolism risk assessment, prophylaxis, and prevention at a university teaching hospital. *American Journal of Medicine*.
4. Yu, S., Galanter, W. T., Lambert, B. L., Borkowsky, S., DiDomenico, R., Schiff, G. D. Consensus list of priority drug-lab linkages for an inpatient asynchronous alert program: results of a Delphi survey.
5. Anthony, M., Nutescu, E., Randhawa, G., Lambert, B. L., et al. Warfarin: Update on Current State of Research, Practice and Education Trends From the Agency for Healthcare Research and Quality - Centers for Education and Research on Therapeutics
6. Yin, H., Lin, S.-J., Muramatsu, N., Crawford, S. Y., Kong, S. X., Lambert, B. L. (submitted). The association between physical functioning and self-rated health in later life: The roles of aging and socioeconomic status. *Journal of health and Social Behavior*

Conference Proceedings

1. Lambert, B. L., Lin, S.-J., Toh, S., Luce, P. A., McLennan, C., La Vigne, R., Fisher, W. M., Dickey, L. W., & Senders, J. W. (2006). Frequency and neighborhood effects on auditory perception of drug names in noise. *Proceedings of NoiseCon 2005*, Institute of Noise Control Engineering, Minneapolis, MN.
2. Carino, C., Jia, Y., Lambert, B. L., West, P. M., & Yu, C. (2005). Mining officially unrecognized side effects of drugs by combining web search and machine learning. *Proceedings of the 2005 ACM Conference on Information and Knowledge Management*, Bremen, Germany:

ACM.

3. Lambert, B. L., Lin, S.-J., Gandhi, S. K., & Chang, K.-Y. (1999). Predicting and preventing drug name confusion errors: A summary of findings. In A. Scheffler (Ed.), *Proceedings of Enhancing Patient Safety and Reducing Errors in Health Care* (pp. 221-225). Chicago, IL: National Patient Safety Foundation.
4. Brewer, W. F., & Lambert, B. L. (1993). The theory-ladenness of observation: Evidence from cognitive psychology. *Proceedings of the 15th Annual Conference of the Cognitive Science Society* (pp. 254-259). Hillsdale, NJ: Lawrence Erlbaum Associates.
5. Tcheng, D. K., Lambert, B. L., Lu, S., & Rendell, L. (1991). AIMS: An adaptive interactive modelling system for supporting engineering decision-making. In L. Birnbaum and G. Collins (Eds.), *Machine Learning: Proceedings of the eighth international workshop* (pp. 645-649). San Mateo, CA: Morgan Kaufmann.
6. Tcheng, D. K., Lambert, B. L., and Lu, S. C-Y. (1989). Generalized recursive splitting algorithms for learning hybrid concepts. In *Proceedings of the Sixth International Workshop on Machine Learning* (pp. 496-498). San Mateo, CA: Morgan Kaufmann.
7. Tcheng, D. K., Lambert, B. L., Lu, S. C-Y., & Rendell, L. (1989). Building robust learning systems by combining induction and optimization. In *Proceedings of the 11th International Joint Conference on Artificial Intelligence* (pp. 806-812). San Mateo, CA: Morgan Kaufmann.

Book Chapters

1. Lambert, B. L., Levy, N. A., & Winer, J. (2009). Keeping the balance and monitoring the self-system: towards a more comprehensive model of medication management in psychiatry (pp. 179-211). In D. Brashers and D. Goldsmith (Eds.), *Communicating to Manage Health and Illness*. New York, Routledge.
2. Schiff GD, Kim S, Abrams R, Cosby, K., Lambert B, Elstein, A. S., Hasler, S., Krosnjak, N., Odwazny, R., Wisniewski, M. F., & McNutt, R. A. (2005). Diagnosing diagnostic errors: Lessons from a multi-institutional collaborative. In *Advances in Patient Safety: From Research to Implementation*. Department of Health and Human Services, Agency for Healthcare Quality and Research, Rockville, MD.
3. Lambert, B. L. (2001). Automatic content analysis of pharmacist-patient interactions using the Theme Machine document clustering system. In M. West (Ed.), *Progress in communication sciences, Vol. 17: Applications of computer content analysis* (pp. 103-122). New York: Ablex.
4. O'Keefe, B. J., Lambert, B. L., & Lambert, C. (1997). Conflict and communication in a research and development unit. In B. D. Sypher (Ed.). *Case studies in organizational communication 2: Perspectives on contemporary work life* (pp. 31-52). New York: Guilford.
5. O'Keefe, B. J., & Lambert, B. L. (1995). Managing the flow of ideas: A local management approach to message design. In B. Burleson (Ed.), *Communication Yearbook 18* (pp. 54-82). Newbury Park, CA: Sage.

Abstracts

1. Lambert, B. L., Lin, S.-J., Toh, S., Luce, P. A., McLennan, C., La Vigne, R., Fisher, W. M., Dickey, L. W., & Senders, J. W. (2005). Frequency and neighborhood effects on auditory perception of drug names in noise. *Acoustical Society of America Journal*, 118, 1955-1955.
2. Lambert, B. L., Chou, C.-H., Chang, K.-Y., Carson, W. T., Tafesse, E. (2003). Antipsychotic use and new-onset Type II diabetes among schizophrenics. *Schizophrenia Research*, 60(1S), 359.

3. Lambert, B. L., Chou, C.-H., Chang, K.-Y., Iwamoto, T., & Tafesse, E. (2002, October). Assessing the risk of antipsychotic-induced Type II diabetes among schizophrenics: A matched case-control study. *European Neuropsychopharmacology*, 12 (Suppl. 3), S307-S308.
4. Viswanathan, H., & Lambert, B. L. (2001, March/April). Management of hypertension from the patient's perspective. *Journal of the American Pharmaceutical Association*, 2, 329.
5. Lambert, B. L., Chang, K.-Y., Lin, S.-J., Gupta, P. (2000). Effect of prescribing frequency, neighborhood frequency, and neighborhood density on pharmacists' visual perception of drug names [abstract]. *PharmSci*, 2, S-1276.
6. Lambert, B. L., Lin, S.-J., Gandhi, S. K., & Chang, K.-Y. (1998). Effects of similarity on pharmacists' recall and recognition of drug names [abstract]. *PharmSci*, 1, S-1333.
7. Lambert B. L., Lin, S.-J., & Gandhi, S. K. (1997). Using normalized edit distance to assess the likelihood of look-alike and sound-alike medication errors [abstract]. *Pharmaceutical Research*, 14, S-233.
8. Brewer, W. F., & Lambert, B. L. (1992). The theory-ladenness of observation: Evidence from cognitive psychology [abstract]. *International Journal of Psychology*, 27, 526.

Grants/Contracts Awarded (External)

1. Cavallari warfarin challenge grant (AHRQ pending)
2. Cavallari warfarin adherence grant (NHLBI pending)
3. Pickard and Wilke Novartis pharmacoepi (pending)
4. Nutescu, E. A., Bautista, A., Schumock, G. T., Lambert, B. L. (2009-2010). Barriers to appropriate anticoagulation with warfarin in orthopedic surgery. OrthoMacNeil. (pending).
5. Schiff clinical documentation (AHRQ, pending)
6. Walton, S., Schumock, G., Pickard, S., Lambert, B. (8%), Galanter, W. (2009-2010). Determinants of perceived and actual knowledge of evidence and other factors that influence off-label prescribing of antipsychotics. Agency for Healthcare Research and Quality. \$718,765. Not funded.
7. Lambert, B.L., Schiff, G.D., Gibbons, R.D., et al. (2007-2011). Tools for optimizing prescribing, monitoring and education (TOP-MED). Center for Education on Research and Therapeutics, Agency for Healthcare Research and Quality. \$4,000,000.
8. Liu, K.-L., Lambert, B. L., Yu, C. (2007-2009). *Reducing drug name confusion with better search software*. National Center for Research Resources (SBIR Phase II Award). \$700,000.
9. Schiff, G. D., Lambert, B. L., Galanter, W. Koronkowski, M. Edison, M. et al. (2006-2008). Formulary leveraged improved prescribing (FLIP). Attorney General Prescriber and Consumer Education Grant Program, \$400,000.
10. Liu, K.-L., Lambert, B. L., Yu, C. (2005). *Reducing drug name confusion with better search software*. National Center for Research Resources (SBIR Phase I Award). \$125,000.
11. Lambert, B. L., Schiff, G., Lamkin, L. (2005-2006). *Regional medication safety initiative: Focus on community pharmacy. Enhancing communication and coordination between hospital-based clinicians, community pharmacies, and outpatient physician offices*. The Michael Reese Health Trust. \$100,000
12. Lambert, B. L., Luce, P. A., Yu, C., Lin, S.-J., Tchong, D. K., Gibbons, R. (2003-2007). *Auditory perception of drug names: Neighborhood effects*. U. S. Agency for Healthcare Research and Quality. \$1,693,166.

13. Lambert, B. L. (2001-2003). *Antecedents and consequences of antipsychotic-induced weight gain among U.S. veterans: Drug switching, noncompliance, relapse, and onset of obesity-related complications*. Bristol-Myers Squibb, \$137,954.
14. Lambert, B. L. & Yu, C. (2001-2002). *Studies of text categorization and clustering in support of the TIMSS-R study of math and science*. LessonLab, Inc. \$73,679.
15. Lambert, B. L. (2001). *Technologies of the self: Examining the intersection of medication, identity, and illness (conference)*. Pharmacia Corp. \$8200.
16. Lambert, B. L. (2000). *Pilot studies of text categorization and automated content analysis in support of the TIMSS-R study of math and science*. LessonLab, Inc. \$30,000.
17. Lambert, B. L. (1999-2000). *Pre-approval screening of USAN names*. United States Adopted Names Council (USANC). \$24,125.
18. Lambert, B. L., Cohen, M., Gupta, P. Schiff, G., & Yu, C. (1999-2000). *Theory and methods for minimizing drug name confusion errors*. National Patient Safety Foundation. \$99,958.
19. Lambert, B. L., & Gupta, P. (1999). *Effects of prescribing frequency, neighborhood frequency, and neighborhood density on visual perception of drug names*. Latiolais Leadership Grants Program. \$24,705.
20. Boring, D., & Lambert, B. L. (1999). *Development of methods for assessing the cognitive toxicity of proposed drug names*. U. S. Food and Drug Administration. \$25,000.
21. Lambert, B. L. (1998-2000). *Searching for look-alike and sound-alike drug names: A technical testing agreement*. Institute for Safe Medication Practices. \$38,874.
22. Lambert, B. L. (1997). *Predicting look- and sound-alike medication errors*. Drug Information Association. \$24,937.
23. Lambert, B. L. & Gandhi, S. K. (1997). *Look- and sound-alike medication errors: A Psychological investigation using computerized tests*. U. S. Pharmacopeia Fellowship Program. \$15,000.
24. Boring, D. & Lambert, B. L. (1997). *Development of methods to review proposed trademark names*. Review Science Research Grant. U. S. Food and Drug Administration. \$5000.
25. Lambert, B. L. (1996). *Enhancing compliance in community pharmacy: A four state demonstration project*. Illinois Pharmacists Association/Eli Lilly Company/PCS Health Systems, Inc. \$8000.
26. Salmon, J. W., Lambert, B. L., & Stubbings, J. (1994). *Factors affecting antibiotic prescribing in a managed care setting*. Abbott Laboratories. \$19,000.
27. Lambert, B. L. (1994). *Patients' perceptions of pharmacist hypertension compliance-gaining messages*. The Upjohn Company. \$2628.
28. Lambert, B. L. (1992). *Face and politeness in pharmacist-physician interaction*. American Association of Colleges of Pharmacy/Burroughs-Wellcome/American Foundation for Pharmaceutical Education, Grant Program for New Investigators. \$5000.

Grants Awarded (Internal)

1. Lambert, B. L. & Levy, N. A. (1998). *Identity themes in the management of antipsychotic drug therapy: Effects of patient and physician gender*. Program for Mental Health Services Research on Women and Gender, Research Infrastructure Support Program (RISP), Department of Psychiatry, University of Illinois at Chicago (NIMH Grant #R24 MH54212-02), \$9,824.
2. Lambert, B. L. & Levy, N. A. (1997). *Identity themes in the management of antipsychotic drug therapy: Effects of patient and physician gender*. Program for Mental Health Services Research

on Women and Gender, Research Infrastructure Support Program (RISP), Department of Psychiatry, University of Illinois at Chicago (NIMH Grant #R24 MH54212-02), \$14,249.

3. Lambert, B. L. (1997). *Look- and sound-alike medication errors: Experiments with lay people*. UIC Campus Research Board. \$13,324.
4. Lambert, B. L. (1994). *Special small research equipment competition: Proposal for wireless microphones and camcorders*. University of Illinois at Chicago, Campus Research Board, \$2549.
5. Lambert, B. L. (1994). *Living with chronic illness: Experience with medication in everyday life*. Office of the Dean, College of Pharmacy, University of Illinois at Chicago, \$1080.
6. Lambert, B. L. (1993). *Message design logic and pharmacist-patient counseling*. University of Illinois at Chicago, Campus Research Board, \$7720.

Patents

Lambert, B. L. (March 4, 2003). *Apparatus, method, and product for multi-attribute drug comparison*. U. S. Patent No. 6,529,892.

Non-Refereed Publications

1. Lambert, B. L. (2008). *Recent Developments in the Prevention and Detection of Drug Name Confusion*. In Hicks R. W., Becker S. C., Cousins D. D. (Eds.). *MEDMARX data report. A report on the relationship of drug names and medication errors in response to the Institute of Medicine's call for action (pp. 10-15)*. Rockville, MD: Center for the Advancement of Patient Safety, US Pharmacopeia.
2. Liang, B. A., Alper, E., Hickner, J., Schiff, G., Lambert, B. L., Gleason, K., Coleman, E. A., Sokol, P. E., Toepp, M. C., Meyer, M., Jette, C. G. (2008). *The physician's role in medication reconciliation: Issues, strategies and safety principles*. American Medical Association.
3. Lambert, B. L. (1998). [Review of the book *The intelligent patient's guide to the doctor-patient relationship*]. *Journal of Multilingual and Multicultural Development*, 19, 343-346.
4. Lambert, B. L. (1998). *Pharmacist-physician interaction: Advantages and disadvantages of being direct*. In F. J. Tromp (Ed.), *Pharmaceutical care in disease management: Improving patient outcomes by pharmacist intervention* (pp. 1-13). Proceedings of the community pharmacy section, World Congress of Pharmacy and Pharmaceutical Sciences. Vancouver, CA: International Pharmaceutical Federation (FIP).
5. Lambert, B. L. (1998). [Review of the book *Drugs and narcotics in history*]. *Social Science & Medicine*, 46, 147-148.
6. Lambert, B. L. (1996). [Review of the book *Looking into community pharmacy: Identifying effective communication skills in pharmacist-patient consultations*]. *Health Communication*, 8, 105-108.
7. Lambert, B. L. (1995). [Review of the book *Communication skills in pharmacy practice: A practical guide for students and practitioners, Third edition*]. *Journal of Pharmacy Teaching*, 4, 73-75.
8. Hatoum, H. H., Hutchinson, R., & Lambert, B. L. (1993). OBRA '90: Patient counseling by pharmacists is required. *U.S. Pharmacist*, 18, 76-86.
9. Lambert, B. L. (1993). *Pharmacist-physician interactions in the face of drug labeling changes*. In *Coping with the unexpected: A pharmacologic and psychological approach* (p. 12). New York: Gem Communication.

10. Lambert, B. L. (1991). [Review of the book *Pragmatics and natural language understanding*]. *Quarterly Journal of Speech*, 77, 382-383.

Conference Papers/Posters

1. Lambert, B. L., Galanter, W., Jung, C., Yu, S., & Schiff, G. D. (2009, December). *Medication-laboratory linked computerized alerts for gadolinium and radiocontrast imaging in patients with chronic kidney disease (CKD): Effects on orders and study completion*. Poster to be presented at the American Society of Health System Pharmacists 2009 Midyear Meeting, Las Vegas, NV.
2. Yu, S., Galanter, W. L., Lambert, B. L., Schiff, G. D., Borkowsky, S. (2009, December). *Consensus list of priority drug-lab linkages for an inpatient asynchronous alert program: results of a Delphi survey*. Poster to be presented at the American Society of Health System Pharmacists 2009 Midyear Meeting, Las Vegas, NV.
3. Galanter, W. L., Boddipalli, V., Kho, A., Trick, B., Lambert, B. L. (2009, September). *Patterns of patient of migration between three urban hospitals in Chicago*. Paper presented at the Midwest Society of General Internal Medicine. September 17, 2009.
4. Lambert, B. L., Schiff, G. D., Galanter, W., Yu, S., DiDomenico, R., Nutescu, E. *Monitoring the risk of heparin-induced thrombocytopenia by linking laboratory and pharmacy data*. Poster presented at the Agency for Healthcare Research and Quality 2009 Annual Conference. Bethesda, MD, September 14-15, 2009.
5. Duhig J, Edison M, Galanter W, Koronkowski M, Lambert BL, Lodolce A, Pickard AS, Wilke CT, Schiff G. *Conceptual issues in the development of a measure of formulary culture*. Paper presented at ISPOR 14th Annual International Conference, Orlando, FL, May 16-20, 2009.
6. Schiff G, Duhig J, Edison M, Galanter W, Koronkowski M, Lambert BL, Lodolce A, Pickard AS, Wilke CT. *Formulary culture survey: Measuring the temperature of clinicians' boiling blood*. Poster presented at SGIM 32nd Annual Meeting, Miami Beach, FL, May 13-16, 2009.
7. Liu, X. F., Galanter, W., Lambert, B. L. (2009, April). *An analysis of computer alerts suggesting oral medication use during computerized order entry of intravenous (IV) medications*. Poster presented at the 2009 ACCP/ESCP International Congress on Clinical Pharmacy (April 24–28) in Orlando, FL.
8. Lambert, B. L. (2008, October). *Social networking for practicing clinicians: Speeding the translation of evidence into practice*. Internet2 Annual Meeting, October 15, 2008, New Orleans, LA.
9. Lambert, B. L., Dickey, L. W., Fisher, W. M., Gibbons, R. D., Lin, S.-J., Luce, P. A., McClennan, C. T., Senders, J. W., Yu, C. T. (2008, October). *Nurses' auditory perception of drug names*. Academy of Medical-Surgical Nurses, October 3, 2008. Nashville, TN.
10. Lambert, B. L., Dickey, L. W., Fisher, W. M., Gibbons, R. D., Lin, S.-J., Luce, P. A., McClennan, C. T., Senders, J. W., Yu, C. T. (2008, September). *Family physicians' auditory perception of drug names: Effect of noise, familiarity and similarity*. American Academy of Family Physicians Scientific Assembly, September 17, 2008. San Diego, CA.
11. Galanter, W. L., Lambert, B. L., Schiff, G. D. (2008, September). *The effectiveness of medication-laboratory linked computerized alerts for gadolinium and radiocontrast imaging in patients with chronic kidney disease*. 2008 Society for General Internal Medicine Midwest Regional Meeting, September 25-26, Chicago, IL.
12. Lambert, B. L. (2008, May). *Success stories of former NPSF grantees*. National Patient Safety Foundation Annual Patient Safety Congress, May 15, 2008, Nashville, TN.
13. Lambert, B. L. (2008, May). *Characteristics of a winning grant proposal at NPSF (or anywhere else)*. National Patient Safety Foundation Annual Patient Safety Congress, May 15, 2008,

Nashville, TN.

14. Lambert, B. L., Lin, S.-J., McClennan, C. T., Luce, P. A., Dickey, L. W., Fisher, W. M., Yu, C. T., Senders, J. W., Gibbons, R. D. (2008, March). *Auditory perception of drug names: Effects of noise, familiarity and similarity*. Annual Meeting of the American Pharmacists Association, March 14-17, 2008. San Diego, CA.
15. Lambert, B. L., Lin, S.-J., Toh, S., Luce, P. A., McLennan, C., La Vigne, R., Fisher, W. M., Dickey, L. W., & Senders, J. W. (2007, May). *Auditory perception of drug names*. Paper presented at Annual Congress of the National Patient Safety Foundation, May 4, 2007, Washington, D.C.
16. Yin, H. Lin, S.-J., Hedeker, D. R., Crawford, S. Y., Kong, S. X., Lambert, B. L., Muramatsu, N. (2006, November) *Heterogeneity in health perception among the oldest old*. American Public Health Association Annual 134th Meeting, Boston, MA, November 6, 2006.
17. Yin, H. Lin, S.-J., Hedeker, D. R., Crawford, S. Y., Kong, S. X., Lambert, B. L., Muramatsu, N. (2006, November) *Trajectory of self-rated health among the oldest old*. American Public Health Association Annual 134th Meeting, Boston, MA, November 6, 2006.
18. Lambert, B. L., Lin, S.-J., Toh, S., Luce, P. A., McLennan, C., La Vigne, R., Fisher, W. M., Dickey, L. W., & Senders, J. W. (2006, September). *Auditory perception of drug names*. Poster presented at Translational Research at UIC Conference, Chicago, IL, September 22, 2006.
19. Lambert, B. L., Lin, S.-J., Toh, S., Luce, P. A., McLennan, C., La Vigne, R., Fisher, W. M., Dickey, L. W., & Senders, J. W. (2006, June). *Auditory perception of drug names*. Poster presented at AHRQ Patient Safety and Health Information Technology Conference, Washington, DC, June 5-6, 2006.
20. Carino, C., Jia, Y., Lambert, B. L., West, P. M., & Yu, C. *Mining officially unrecognized side effects of drugs by combining web search and machine learning*. Paper to be presented at the 2005 ACM Conference on Information and Knowledge Management. Bremen, Germany, October 31 – November 5, 2005.
21. Lambert, B. L., Lin, S.-J., Toh, S., Luce, P. A., McLennan, C., La Vigne, R., Fisher, W. M., Dickey, L. W., & Senders, J. W. (2005, October). *Frequency and neighborhood effects on auditory perception of drug names in noise*. Proceedings of NoiseCon 2005, Institute of Noise Control Engineering, Minneapolis, MN, October 17-19, 2005.
22. Tan, J., Lin, S.-J., Lambert, B. L., Sclove, S. (2005, May). *The main and interaction effects of patient and physician characteristics in influencing the prescribing of antidepressants*. ISPOR 10th Annual International Meeting, Washington, DC, May 15, 2005.
23. Tan, J., Lin, S.-J., Lambert, B. L., Sclove, S. (2005, May). *Comparing exhaustive CHAID classification tree and forward stepwise logistic regression (lr) in explaining the prescribing of antidepressants*. ISPOR 10th Annual International Meeting, Washington, DC, May 15, 2005.
24. Lin, S.-J., Tan, J., Toh, D., & Lambert, B. L. (2005, April) *Frequency estimates from prescription drug datasets*. Poster presented at the Annual Meeting of the American Pharmacists Association, Orlando, FL, April 1, 2005.
25. Tan, J., Lin, S.-J., Lambert, B. L., Toh, D. (2004, July). *An evaluation of the quality of the USP/ISMP Medication Error Reporting Program*. Poster presented at the Midwest Pharmacy Administration Conference, West Lafayette, IN, July 29, 2004.
26. Toh, D., Tan, J., Lambert, B. L., Lin, S.-J. (2004, July). *Assessing the quality of published case reports of look-alike and sound-alike medication errors*. Poster presented at the Midwest Pharmacy Administration Conference, West Lafayette, IN, July 29, 2004.
27. Lambert, B. L., Schiff, G., Lin, S.-J., Tan, H.-K., Crouch, P. (2003, October). *Making formularies safer by identifying sources of harmful drug product confusion*. Poster presented at Chicago Patient Safety Forum's Annual Patient Safety Showcase. Chicago, IL.

28. Cunningham, F., Lambert, B., Miller, D. R. Dalack, G., Kim, J. B., Hur, K. (2003, August). *Antipsychotic induced diabetes in veteran schizophrenic patients*. Paper presented at the 19th International Conference on Pharmacoepidemiology, August 24, 2003. Philadelphia, PA.
29. Lambert, B. L., Chang, K.-Y., Carson, W. T., Tafesse, E. (2003, May). *Antipsychotic-induced hyperlipidemia among people with schizophrenia*. Poster presented at the American Psychiatric Association's 156th Annual Meeting, San Francisco, CA.
30. Lambert, B. L., Chou, C.-H., Chang, K.-Y., Carson, W. T., Tafesse, E. (2003, March). *Antipsychotic use and new-onset Type II diabetes among schizophrenics*. Paper presented at the IXth International Congress on Schizophrenia Research. Colorado Springs, CO.
31. Lambert, B. L., Chou, C.-H., Chang, K.-Y., Iwamoto, T., Tafesse, E. (2002, October). *Assessing the risk of antipsychotic-induced Type II diabetes among schizophrenics: A matched case-control study*. Poster presented at the 15th European Neuropsychopharmacology Conference. Barcelona, Spain.
32. Lambert, B. L., Chang, K.-Y., Gupta, P., Lin, S.-J. (2002, April). *Effects of similarity neighborhoods on pharmacists' visual perception of handwritten drug names*. National Patient Safety Foundation Researcher Symposium, Annenberg IV: Patient Safety—Let's Get Practical. Indianapolis, IN.
33. Lambert, B. L. (2002, March). *What should one expect from a new ontology?* Talk presented at New Ontologies Conference, Urbana, IL.
34. Lambert, B. L., Yu, C., Liu, F., & Waivio, R. I. (2002, January). *Computerized discourse analysis of TIMSS-R lesson transcripts*. UIC Conference on Teaching, Learning, Technology, & Teacher Development, Chicago, IL.
35. Dalal, M. R., Lambert, B. L. (2001, May). *Implementing Rasch analysis in psychometric evaluation of patient-physician interaction scale*. Paper presented at the 6th Annual International Meeting of the International Society for Pharmaceutical Outcomes Research, Arlington, VA.
36. Viswanathan, H. N., Lambert, B. L. (2001, March). *Management of hypertension from the patient's perspective*. Paper presented at the Annual Meeting of the American Pharmaceutical Association, San Francisco, CA.
37. Brewer, W. F., & Lambert, B. L. (2000, November). *The theory-ladenness of observation and the theory-ladenness of the rest of the scientific process*. Paper presented at the Seventeenth Biennial Meeting of the Philosophy of Science Association, Vancouver, British Columbia, Canada.
38. Lambert, B. L., Chang, K.-Y., Lin, S.-J., Gupta, P. (2000, October). *Effect of prescribing frequency, neighborhood frequency, and neighborhood density on pharmacists' visual perception of drug names*. Paper presented at the Annual Meeting of the American Association of Pharmaceutical Scientists, Indianapolis, IN.
39. Lambert, B. L., Winer, J., & Levy, N. A. (2000, October). *Examining the intersection of medication, identity and illness in psychiatric medication management*. Paper to be presented at the University of Illinois Conference on Health Communication, Urbana, IL.
40. Lambert, B. L., Chang, K.-Y., Lin, S.-J., & Gandhi, S. K. (2000, January). *New technologies for preventing drug name confusion errors*. Poster presented at Partnerships for Health in the New Millennium: Launching Healthy People 2010, Washington, DC.
41. Lambert, B. L. (1999, November). *Teaching social and behavioral science to pharmacy students*. Paper presented to the Annual Convention of the National Communication Association, Chicago, IL.
42. Lambert, B. L. (1998, November). *Semi-automated content analysis of pharmacist-patient interactions using the Theme Machine document clustering system*. Paper presented to the Annual Convention of the National Communication Association, New York, NY.
43. Lambert, B. L., Lin, S.-J., Gandhi, S. K., & Chang, K.-Y. (1998, November). *Effects of similarity*

- on pharmacists' recall and recognition of drug names*. Paper presented at the Annual Meeting of the American Association of Pharmaceutical Scientists, San Francisco, CA.
44. Lambert, B. L., Lin, S.-J., Gandhi, S. K., & Chang, K.-Y. (1998, November). *Predicting and preventing drug name confusion errors: A summary of findings*. Paper presented at the Second Annenberg/AAAS Conference on Enhancing Patient Safety and Reducing Errors in Health Care, Rancho Mirage, CA.
 45. Gandhi, S. K., Salmon, J. W., Zhao, S. Z., Lambert, B. L., Gore, P. G., Conrad, K. (1998, October). *Comparison of SF-12 and SF-36 as generic health-related quality of life measures in osteoarthritis*. Paper presented at Educational Conference of the Academy of Managed Care Pharmacy, Chicago, IL.
 46. Butin, D. N., Zhao, S. Z., Carr, B. C., Moran, D. P., Dedhiya, S. D., Kizis, F. J., Lambert, B. L., & Jacobs, R. P. (1998, September). *Arthritis care from the primary care physician's point of view*. Paper presented at the Annual Meeting of the European League Against Rheumatism, Geneva, Switzerland.
 47. Butin, D. N., Zhao, S. Z., Carr, B. C., Moran, D. P., Dedhiya, S. D., Lambert, B. L., & Jacobs, R. P. (1998, September). "Arthritis is pain." *Experience of arthritis from the patient's point of view*. Paper presented at the Annual Meeting of the European League Against Rheumatism, Geneva, Switzerland.
 48. Gandhi, S. K., Salmon, J. W., Zhao, S. Z., Lambert, B. L., Gore, P., & Conrad, K. (1998, May). *Psychometric evaluation of SF-12 in osteoarthritis clinical trials*. Paper presented at the Third Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Philadelphia, PA.
 49. Gandhi, S. K., Salmon, J. W., Zhao, S. Z., Lambert, B. L., Gore, P., & Conrad, K. (1998, May). *SF-12 osteoarthritis-specific health index: Development and validation*. Paper presented at the Third Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Philadelphia, PA.
 50. Lambert, B. L. (1997, November). *Using normalized edit distance to assess the likelihood of look- and sound-alike medication errors*. Paper presented at the Annual Meeting of the American Association of Pharmaceutical Scientists. Boston, MA.
 51. Lambert, B. L. (1997, May). *Psychological basis of medication errors: Computer screening for look- and sound-alike names*. Paper presented at the Sixth International Conference on Language and Social Psychology. Ottawa University, Ottawa, CA.
 52. Lambert, B. L. (1996, November). *Assessing competence and effectiveness in health care interactions* (panel respondent). Paper presented at the 82nd Annual Convention of the Speech Communication Association, San Diego, CA.
 53. Lambert, B. L. (1996, November). *Influence and control in health communication: Autonomy as a core identity issue for patients and their health care providers*. Paper presented at the 82nd Annual Convention of the Speech Communication Association, San Diego, CA.
 54. O'Keefe, B. J., Bonito, J. A., & Lambert, B. L. (1996, November). *Peer feedback in a collaborative writing situation: Identity themes as resources for generating evaluations*. Paper presented at the 82nd Annual Convention of the Speech Communication Association, San Diego, CA.
 55. Lambert, B. L., Salmon, J. W., Stubbings, J., Gilomen-Study, G., Valuck, R., & Kezlarian, K. (1996, November). *Factors affecting antibiotic prescribing in a managed care setting*. Paper presented at the Annual Meeting of the American Public Health Association, New York, NY.
 56. Lambert, B. L. (1996, May). *The Theme Machine: Theoretical foundation and summary of methods*. Paper presented at the 46th Annual Conference of the International Communication Association, Chicago, IL.

57. Lambert, B. L. (1995, November). *Unifying research and teaching around the patient as a central construct: Continuing the dialogue on communication scholars in health care*. Paper presented at the 81st Annual Convention of the Speech Communication Association, San Antonio, TX.
58. Lambert, B. L. (1995, July). *Sociodemographic influences on pharmacist-physician interaction*. Paper presented at 1995 Annual Meeting of the American Association of Colleges of Pharmacy, Philadelphia, PA.
59. Lambert, B. L. (1995, May). *Face and politeness in pharmacist-physician interaction: Part II*. Paper presented at the 45th Annual Conference of the International Communication Association, Albuquerque, NM.
60. Lambert, B. L. (1994, November). *The role of communication scholars in building a new health care community*. Paper presented at the 80th Annual Convention of the Speech Communication Association, New Orleans, LA.
61. Lambert, B. L., & Lee, J. Y. (1994, November). *Patient perceptions of pharmacy students' hypertension compliance gaining messages: Effects of message design logic and content themes*. Paper presented at the 80th Annual Convention of the Speech Communication Association, New Orleans, LA.
62. Lambert, B. L. (1994, October). *Patient perceptions of pharmacy students' hypertension compliance gaining messages*. Paper presented at the Wintergreen Research Conference III, University of Maryland Center on Drugs and Public Policy, Wintergreen, VA.
63. Brewer, W.F., & Lambert, B. L. (1994, October). *The theory-ladenness of data: Evidence from cognitive psychology*. Paper presented at the Annual Meeting of the Society for Social Studies of Science, New Orleans, LA.
64. Lambert, B. L. (1993, November). *Reporting allergies and recommending alternatives: Directness and deference in pharmacist-physician interaction*. Paper presented at the 79th Annual Convention of the Speech Communication Association, Miami, FL.
65. Brewer, W. F., & Lambert, B. L. (1993, June). *The theory-ladenness of observation: Evidence from cognitive psychology*. Paper presented at the 15th Annual Conference of the Cognitive Science Society, Boulder, CO.
66. O'Keefe, B. J., Lambert, B., & Lambert, C. (1993, May). *Effect of message design logic on perceived communication effectiveness in supervisory relationships*. Paper presented at the 43rd Annual Conference of the International Communication Association, Washington, D.C.
67. Lambert, B. (1992, November). *Functional abstraction and plan-based modelling*. Paper presented at the 78th Annual Convention of the Speech Communication Association, Chicago, IL.
68. Brewer, W. F., & Lambert, B. L. (1992, July). *The theory-ladenness of observation: Evidence from cognitive psychology*. Paper presented at the 25th International Congress of Psychology, Brussels, Belgium.
69. Lambert, B. (1992, July). *Face and politeness in pharmacist-physician interaction*. Paper presented to the 93rd Annual Meeting of the American Association of Colleges of Pharmacy, Washington, D.C.
70. Lambert, B. L. & O'Keefe, B. J. (1990, November). *Modelling message design*. Paper presented at 76th Annual Convention of the Speech Communication Association, Chicago, IL.
71. Lambert, B. L. (1990, October). *Semantic and pragmatic approaches to multi-agent coordination in product realization*. Paper presented at the Third Annual Organizational Communication Mini-Conference, Purdue University, West Lafayette, IN.
72. O'Keefe, B. J., & Lambert, B. L. (1989, November). *The effect of message design logic on the communication of intention*. Paper presented at the 75th Annual Convention of the Speech

Communication Association, San Francisco, CA.

73. Lambert, B. L. (1989, March). *Normative, descriptive, and generative aspects of practical theory*. Paper presented at the 10th Annual Temple Discourse Conference, Philadelphia, PA.

Invited Lectures

1. “Success stories from the National Patient Safety Foundation research program.” Board of Directors and Board of Governors, National Patient Safety Foundation, Boston, MA, October 13, 2008.
2. “Auditory perception of drug names: Effects of noise, familiarity, frequency and similarity.” Department of Psychology, University at Buffalo, September 24, 2008.
3. “The effect of industry promotion on evidence-based medicine.” Northwestern University Graduate Program in Healthcare Quality and Patient Safety, Chicago, IL, July 25, 2008.
4. “The effect of industry promotion on evidence-based medicine.” Keynote Presentation, Midwest Social and Administrative Pharmacy Conference, Medication Use, Safety and Effectiveness, Chicago, IL, July 24, 2008.
5. “False and misleading pharmaceutical advertising and promotion?” UIC Medical Center Clinical Ethics Consult Center Annual Seminar: The interdependence of healthcare and the pharmaceutical industry, Chicago, IL, March 6, 2008.
6. “The impacts of power gradients on communication,” Maryland Patient Safety Center’s Handoff and Transitions Learning Network Session, Ellicott City, MD, February 6, 2008.
7. “Name safety evaluation: What does research tell us?” Institute for Safe Medication Practices’ National Summit on Managing Drug Name Confusions, Philadelphia, PA, October 9, 2007.
8. “Auditory perception of drug names,” National Patient Safety Foundation Annual Congress, Washington, DC, May 4, 2007.
9. “Medication reconciliation panel discussion,” Society for General Internal Medicine, Toronto, Ontario, Canada, April 27, 2007.
10. “The impacts of power gradients on communication,” IHA Safety Connections: Relaying Lessons Learned, Lisle, IL, November 13, 2006.
11. “Medication reconciliation in Chicago,” Chicago Donor’s Forum, Chicago, IL, May 24, 2006.
12. “Regional medication safety initiative: Enhancing communication and coordination between hospital-based clinicians, community pharmacies, and outpatient physician offices.” Michael Reese Health Trust Peer Review Meeting, Chicago Patient Safety Forum Regional Medication Safety Initiative, Chicago, IL, October 27, 2005.
13. “Frequency and neighborhood effects on auditory perception of drug names,” NoiseCon, Minneapolis, MN, October 19, 2005.
14. “Medication reconciliation: Looking forward.” First Annual 2005 Outcomes Congress, Improving Patient Safety: Medication Reconciliation, Bloomington, IL, October 18, 2005.
15. “Regional medication safety initiative: Enhancing communication and coordination between hospital-based clinicians, community pharmacies, and outpatient physician offices.” Planning Meeting, Chicago Patient Safety Forum Regional Medication Safety Initiative, Chicago, IL, September 19, 2005.
16. “Making formularies safer by proactively identifying similar pairs of hazardous drug products.” Patient Safety Conference Call, OSF Healthcare, Peoria, IL, August 19, 2005.
17. “Introduction to patient safety for incoming medical residents,” House Staff Orientation, UIC

- Medical Center, Chicago, IL, June 23 and 30, 2005.
18. "Preventing patient harm and predicting FDA behavior." Trademark group, Eli Lilly, Inc., Indianapolis, IN, May 31, 2005.
 19. "Drug name confusion, medication reconciliation and medication safety," Illinois Hospital Association Patient Safety Learning Collaborative—Medication Reconciliation, First Learning Session, Lisle, IL, February 16, 2005.
 20. "SafeDrugNames.com: Using a web-based drug name search system to minimize the risk of drug name confusions." Copyright and Trademark Committee, Pharmaceutical Research and Manufacturers Association of America (PhRMA). Washington, DC, September 23, 2004.
 21. "Preventing drug product confusion errors: Strategies for the pharmacy buyer." Las Vegas, NV, August 17, 2004.
 22. "Error reporting systems: New directions," National Association of Boards of Pharmacy Centennial Meeting and Celebration, Chicago, IL, April 27, 2004.
 23. "Comments on validation strategies and testing methods used to evaluate new drug names," Public testimony before FDA's Drug Safety and Risk Management Advisory Committee, Rockville, MD, December 4, 2003.
 24. "Predicting and preventing drug name confusions: Strategies for front line practitioners," Mercy Resource Management, Inc. Annual Meeting,, Lisle, IL, October 29, 2003.
 25. "Computer assisted decision analysis in drug naming," Look-Alike/Sound-Alike Health Product Names (LA/SA) Consultative Workshop, Health Canada, Ottawa, CA, October 20-21, 2003.
 26. "Design of safe drug names," US/UK Collaborative Workshop on Design for Patient Safety, Agency for Health Care Research and Quality, Rockville, MD, September 23-24, 2003.
 27. "Computer assisted decision analysis in drug naming," FDA/PhRMA/ISMP Workshop on Evaluating Drug Names for Similarities: Methods and Approaches, Washington, DC, June 26, 2003.
 28. "Recent advances in understanding, predicting, and preventing drug product confusion errors," Illinois Society for Healthcare Risk Management, Peoria, IL, May 2, 2003.
 29. "Predicting and preventing drug name confusions: Strategies for front line practitioners," Illinois Hospital Association's Spotlight on Patient Safety Conference Call, April 17, 2003.
 30. "Planning for a regional medication safety initiative in the Chicago metropolitan area," Patient Safety Committee, Illinois Hospital Association, Naperville, IL, April 3, 2003.
 31. "Predicting and preventing drug name confusions: Strategies for front line practitioners," Department of Pharmacy, Rush Presbyterian St. Luke's Hospital, Chicago, IL, March 14, 2003.
 32. "Predicting and preventing drug name confusions: Strategies for front line practitioners," Grand Rounds, Department of Neurology, University of Illinois at Chicago, Chicago, IL, December 12, 2002.
 33. "Descriptive analysis of the drug name lexicon," Copyright and Trademark Committee, Pharmaceutical Research and Manufacturers Association of America (PhRMA), Pfizer, New York, NY, December 7, 2001.
 34. "Computer-assisted pre-approval screening of proposed drug names: Improving the reliability of the drug name approval process," Developments in Pharmacy Law Seminar XI, American Society of Pharmacy Law, Amelia Island, FL, November 4, 2000.
 35. "Communication between physicians and pharmacists," European Association of Faculties of Pharmacy Symposium on Integrating Pharmaceutical Care into the Curriculum, Lisbon, Portugal, May 13, 2000.
 36. "Using the Theme Machine document clustering system to facilitate content analysis of a large

- database of transcribed classroom talk,” LessonLab, Santa Monica, CA, January 10, 2000.
37. “Automated tools to predict and prevent drug name confusions,” Barnett International Symposium on Pharmaceutical Global Branding. Arlington, VA, May 17, 1999
 38. “The experience of chronic illness from the patient’s point of view,” Student National Pharmaceutical Association Regions III and I Spring Conference: Building the Bridge to the Next Millennium. Chicago, IL, April 10, 1999.
 39. “Predicting drug name confusion errors: Trademarks by the numbers,” Copyright and Trademark Committee, Pharmaceutical Research and Manufacturers Association of America (PhRMA), Pfizer Headquarters, New York, NY, December 16, 1998.
 40. “Predicting and preventing drug name confusion errors: case-control analyses and memory experiments based on computerized measures of similarity,” Special Briefing for Dr. Janet Woodcock, MD, Director, U.S. FDA Center for Drug Evaluation Research. Washington, DC, June 24, 1998.
 41. “Theory and methods for minimizing name confusion errors,” Chicago Area Pharmacy Residents’ Conference, Chicago, IL, June 8, 1998.
 42. “Effect of orthographic and phonological similarity on pharmacists recall and recognition of drug names,” Language Production Group, Beckman Institute for the Advanced Study of Science and Technology, Urbana, IL, April 16, 1998.
 43. “Similarity as toxicity: Hazards associated with look-alike and sound-alike names,” Strategies for error-proofing drug labeling, packaging, and nomenclature: Industry’s role in preventing product-related medication errors. Institute for Safe Medication Practices, Princeton, NJ, April 3, 1998.
 44. “Automated screening for look- and sound-alike medication errors,” FDA Workshop on Minimizing Medical Product Errors: A Systems Approach, National Institutes of Health, Bethesda, Maryland, January 8, 1998.
 45. “How internists can help patients achieve their identity goals,” West Suburban Hospital Medical Center, Oak Park, IL, December 1, 1997.
 46. “Look- and sound-alike medication errors,” Seminar, Department of Pharmaceutics and Pharmacodynamics, University of Illinois at Chicago, October 15, 1997.
 47. “Pharmacist-physician communication: Advantages and disadvantages of being direct.” 57th World Congress of Pharmacy and Pharmaceutical Sciences (FIP), Vancouver, British Columbia, Canada, September 6, 1997.
 48. “Dealing with ‘difficult’ patients in community pharmacy practice: reducing pharmacist stress and improving patient care.” Chicagoland Walgreen's Pharmacists Continuing Education Program, Arlington Heights, IL, July 20 and 26, 1997.
 49. “Predicting look-alike and sound-alike medication errors with computerized screening methods,” Foundation of FDA Pharmacists Annual Meeting, U.S. Food and Drug Administration, Rockville, MD, May 28, 1997.
 50. “How family practice physicians can help patients achieve their identity goals,” West Suburban Hospital Medical Center, Oak Park, IL, April 15, 1997.
 51. “Patient-centered care and the mangle of practice,” Department of Communication, University of Arizona, Tucson, AZ, March 28, 1997.
 52. “Cognitive models of language production,” Department of Communication, University of Arizona, Tucson, AZ, March 26, 1997.
 53. “The Theme Machine: Theory and method,” Department of Communication, University of Arizona, Tucson, AZ, March 27, 1997.
 54. “Self-care consulting: Patient care issues for pharmacists,” 144th APhA Annual Meeting and

- Exposition, Los Angeles, CA, March 8, 1997.
55. "Predicting look and sound-alike medication errors," Special Briefing for the Error Prevention Analysis Task Force, U. S. Food and Drug Administration, Washington, D.C., October 30, 1996.
 56. "Predicting look and sound-alike medication errors," Medication Error Reporting Group, U. S. Pharmacopeia, Washington, D.C., October 30, 1996.
 57. "The role of string similarity in look-alike and sound-alike medication errors," Language Production Group, Beckman Institute for the Advanced Study of Science and Technology, Urbana, IL, September 25, 1996.
 58. "Ongoing patient evaluation: Optimizing patient adherence," Annual Meeting of the Wisconsin Pharmacists Association, Milwaukee, WI, August 15-18, 1996.
 59. "Self-care consulting: Patient care issues for pharmacists," 143rd APhA Annual Meeting and Exposition, Nashville, TN, March 10, 1996.
 60. "Communication, social influence, and the use of prescription drugs," Department of Health Policy and Management, Johns Hopkins School of Public Health, Baltimore, MD, January 31, 1996.
 61. "Communication skills for patient counseling under OBRA 1990," Annual Meeting of the Illinois Council of Health System Pharmacists, Springfield, IL, October 27, 1995.
 62. "Issues in managed care pharmacy," Round Table Moderator, Midwest Managed Health Care Conference, Chicago, IL, November 16, 1994.
 63. "An interactive approach to patient counseling," Lutheran General Hospital, Park Ridge, IL, March 14, 1994.
 64. "Health communication and compliance: The pharmacist as an agent of influence," Department of Speech Communication, University of Illinois at Urbana-Champaign, May 21, 1993.
 65. "Communication skills for patient counseling under OBRA 1990," Dik Drug Educational Expo, Willowbrook, IL, May 19, 1993.
 66. "Communication and patient counseling: Four key communicative tasks," Focus on Pharmacy Practice, Oak Brook, IL, May 12, 1993.
 67. "Teaching communication skills and concepts to pharmacy students," Teachers' Exchange Round Table Session, 94th Annual Meeting of the American Association of Colleges of Pharmacy, San Diego, CA, July 11, 1993.

University or College Committees

Student Discipline Committee, 1996-1998
 Student-Faculty Relations Committee, 1997-2000
 Executive Committee, 1992-1997, 2003-2006, 2007-present
 Educational Policy Committee, 2006-2007
 Director of Graduate Studies, Department of Pharmacy Administration, 1995-1996, 1998-2000
 Committee on Committees (Chair), 1994-1996
 Admissions Committee, 1992-1994
 UIC Chancellor search committee, 2007-2008

Consulting

Pitman-Moore
 DuPont-Merck

Gem Communication, Inc.
 Ringier America, Inc.

Medical Forum, Inc.
Johnson & Johnson/Merck, Inc.
G. D. Searle, & Co.
Walgreen's, Inc.
U.S. Food and Drug Administration
University of Arizona Department of
Communication
Pharmacia Corp.
Glaxo-Wellcome, Inc.
DeFusco & Udelman, LLC
Fitzpatrick, Cella, Harper & Scinto
Paul Episcopo, Ltd.
Weitz & Luxenberg, P.C.
Sheller, P.C.
Institute for Safe Medication Practices

Cap Gemini Ernst & Young
Winston Laboratories
Bristol-Myers Squibb, Inc.
Morris Cody and Associates, Inc.
Novartis, Inc.
Eli Lilly & Co., Inc.
Med-E.R.R.S., Inc.
Timothy Hatton, JD
ISMP Canada
Abbott Laboratories